The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.
BYP - everyone entitled to their opinion but what you are saying can be said against any other company. Status of invoices etc. If you look at Novacyt Financials (below) you can clearly see the healthy state Novacyt is in. This is as of June 2021 so I'd expect it to be better come full results in April! and plus the company has Zero Debt! Which a lot of the other "better" companies cannot say.
- https://novacyt.com/wp-content/uploads/2021/09/Novacyt-Interim-Accounts-June-2021-English.pdf
Posted this earlier!
ITS ALL RELATIVE! You hear Sales Plunging in 2022 but that is expected across the board in a lot of Pharmaceutical / Diagnostic Companies. A lot of these companies profited massively from Covid-19 and as that comes to an end where its more like the Flu rather than a pandemic, you will see revenues drop, not just Novacyt so can everyone who boasts about revenue drop etc just calm down.
Many (like myself) was hoping for a Home-run RNS. Today wasn't that but yet it was still a very positive RNS.
Rev for FY21 was £95m,
Rev for FY22 expected to be at least £50m (if not more) including Covid and Non-Covid 19 tests.
Rev for FY23 I would expect some still to be generated by Covid-19 test but this is when majority of their revenue would be from Non-Covid 19 tests but by then they would have developed a string of new Non-Covid19 tests and hinted by the new CEO, becoming a 'Market-led', I would expect at least £50m worth of revenue.
Net Assets (as of June 2021) Totalled £140m
Cash (as of 31st Dec 2021) Totalled £101m
IF YOU COMPARE THIS TO 'Oxford Nanopore Technologies'
Revenue expected for FY21 is £126m
Net Assets (as of April 2021) is £350m
Cash expecting to be roughly £300-350m
They are valued just shy of £4bn at the moment! So even if you say Novacyt is doing a quarter of what Oxford is doing (clearly doing more) then they are worth £1 Billion....Even if you think Novacyt is doing half of a quarter (so an eighth) they should be valued at £500m!! We are currently valued at £150m! How nuts is this?! It's incredibly under-valued.
Appreciate this has been a frustrating year for everyone who has invested in Novacyt but clearly there is something wrong with the Market / Traders and not just Novacyt Board.
ITS ALL RELATIVE! You hear Sales Plunging in 2022 but that is expected across the board in a lot of Pharmaceutical / Diagnostic Companies. A lot of these companies profited massively from Covid-19 and as that comes to an end where its more like the Flu rather than a pandemic, you will see revenues drop, not just Novacyt so can everyone who boasts about revenue drop etc just calm down.
Many (like myself) was hoping for a Home-run RNS. Today wasn't that but yet it was still a very positive RNS.
Rev for FY21 was £95m,
Rev for FY22 expected to be at least £50m (if not more) including Covid and Non-Covid 19 tests.
Rev for FY23 I would expect some still to be generated by Covid-19 test but this is when majority of their revenue would be from Non-Covid 19 tests but by then they would have developed a string of new Non-Covid19 tests and hinted by the new CEO, becoming a 'Market-led', I would expect at least £50m worth of revenue.
Net Assets (as of June 2021) Totalled £140m
Cash (as of 31st Dec 2021) Totalled £101m
IF YOU COMPARE THIS TO 'Oxford Nanopore Technologies'
Revenue expected for FY21 is £126m
Net Assets (as of April 2021) is £350m
Cash expecting to be roughly £300-350m
They are valued just shy of £4bn at the moment! So even if you say Novacyt is doing a quarter of what Oxford is doing (clearly doing more) then they are worth £1 Billion....Even if you think Novacyt is doing half of a quarter (so an eighth) they should be valued at £500m!! We are currently valued at £150m! How nuts is this?! It's incredibly under-valued.
Appreciate this has been a frustrating year for everyone who has invested in Novacyt but clearly there is something wrong with the Market / Traders and not just Novacyt Board.
Yes, previously didn't mention that Q1 rev will be materially impacted
Looks like it does!
https://twitter.com/NovacytGroup/status/1372488458195861505
Does anyone know if our tests can detect this new variant??
https://www.google.com/amp/s/www.forbes.com/sites/joshuacohen/2021/03/17/latest-covid-19-variant-discovered-in-france-isnt-detected-by-standard-pcr-tests/amp/
I've had the same issue on my laptop but seems to be working on my mobile weirdly enough
Could this have been the £460k BUY yesterday???
Not a bad RNS but think everyone was expecting something better hence the drop in sp this morning - current price is too cheap imo and it'll eventually get back to 150/200 mark once tests are approved and big sales figures starts to come in.
Newbie here - does anyone think the drop is down to the audited accounts (up to 31st Dec) due to be released this week?